Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies

Abstract Background Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies. However, the use of allogeneic T cells in CAR therapy poses a challenge due to the risk of graft-v...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yingling Zu, Quan Ren, Jishuai Zhang, Hongchang Su, Qiumei Lu, Yongping Song, Jian Zhou
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-10-01
Col·lecció:	Experimental Hematology & Oncology
Matèries:	Chimeric antigen receptor Nature killer cells CD5 T-cell malignancies
Accés en línia:	https://doi.org/10.1186/s40164-024-00577-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!